WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

European Journal of Cancer

Volumn 32, Issue SUPPL. 4, 1996, Pages

  Alberts, D S ^a,b,c   Speicher, L A ^b,d   Krutzsch, M ^b,c   Wymer, J ^b,c   Capizzi, R L ^b,e   Conlon, J ^b,e   Barrett, A ^b,c   Aickin, M ^b,c,f  

^a College of Medicine   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d WYETH AYERST RESEARCH   (United States)

^e US Bioscience   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

amifostine; antineoplastic agents; antitumour; drug screening assays; radiation protective agents

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; VINBLASTINE; VINCRISTINE;

ARTICLE; BREAST CANCER; CELL PROTECTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MERCAPTOETHYLAMINES; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0029957415     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00313-9     Document Type: Article

References (12)

1. 50(7) doses
2. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721
3. Selective inhibition of the nephrotoxicity of cis-dichlorodiammine platinum (II) by WR-2721 without altering its antitumour properties
4. Time dependence of the selective modulation of cisplatin-induced nephrotoxity by WR-2721 in the mouse
5. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721
6. Biochemical determinants of the cytoprotective effect of amifostine
7. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammine platinum II or cyclophosphamide
8. The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino) ethylphosphorothioic acid (WR-2721)
9. A randomized trial of cyclophosphamide and cisplatin ± amifostine in the treatment of advanced epithelial ovarian cancer
10. Phase II trial of amifostine, cisplatin and vinblastine for metastatic non-small cell lung cancer
11. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
12. 60Co gamma rays in mice